Moderna revises 2025 revenue forecast down by $1B, stock tanks by 20%.
Nobody is shocked even more....
Just as I published my report on Moderna RSV fail yesterday, more news on this topic appeared in the mainstream press, so I felt that’s too important to ignore and wrote this follow up post. $MRNA was down 20% on Monday afternoon, trading at $33.75 per share on some continued “bad” news. By bad, I mean very good news indicating nobody is buying Modern…
Keep reading with a 7-day free trial
Subscribe to Due Diligence and Art to keep reading this post and get 7 days of free access to the full post archives.